Weight gain in children and adolescents during 45 weeks treatment with clozapine, olanzapine and risperidone

@article{Fleischhaker2008WeightGI,
  title={Weight gain in children and adolescents during 45 weeks treatment with clozapine, olanzapine and risperidone},
  author={Christian Fleischhaker and Philip Heiser and Klaus Hennighausen and Beate Herpertz-Dahlmann and Kristian Holtkamp and Claudia Mehler-Wex and Reinhold Rauh and Helmut Remschmidt and Eberhard Schulz and Andreas Warnke},
  journal={Journal of Neural Transmission},
  year={2008},
  volume={115},
  pages={1599-1608}
}
The aim of this study was to evaluate long-term weight gain associated with clozapine, olanzapine, and risperidone treatment and its clinical risk factors in children and adolescents. At four child and adolescent psychiatric departments, the weight and body mass index of initially hospitalized patients (aged 9.0–21.3 years) treated with clozapine (n = 15), olanzapine (n = 8), and risperidone (n = 10) were prospectively monitored for 45 weeks. Clinical risk factors (age, gender, baseline weight… CONTINUE READING